Scarica l'app Stockscreener
4.13
5.28%
-0.23
Dopo l'orario di chiusura:
29.72
25.59
+619.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.36
Aprire:
$4.29
Volume 24 ore:
705.35K
Relative Volume:
0.87
Capitalizzazione di mercato:
$302.87M
Reddito:
-
Utile/perdita netta:
$-98.79M
Rapporto P/E:
-1.263
EPS:
-3.27
Flusso di cassa netto:
$-51.66M
1 W Prestazione:
+11.02%
1M Prestazione:
+4.82%
6M Prestazione:
+574.29%
1 anno Prestazione:
+1,215%
Intervallo 1D:
$4.00
$4.43
Intervallo di 1 settimana:
$3.45
$4.47
Portata 52W:
$0.2404
$5.12
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Nome
Relmada Therapeutics Inc
Settore
Industria
Telefono
646 876 3459
Indirizzo
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.11 | 2.67B | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
7.84 | 433.15M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.25 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
2.7499 | 241.44M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DWLD
Davis Select Worldwide ETF
|
46.90 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Ripresa | Leerink Partners | Outperform |
| 2025-12-22 | Iniziato | Jefferies | Buy |
| 2025-11-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-12-05 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-06-05 | Downgrade | Goldman | Neutral → Sell |
| 2022-10-14 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-14 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-10-14 | Downgrade | Truist | Buy → Hold |
| 2022-10-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-11-18 | Iniziato | Mizuho | Buy |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-10-28 | Downgrade | Goldman | Buy → Neutral |
| 2020-07-14 | Iniziato | Oppenheimer | Outperform |
| 2020-05-04 | Iniziato | SunTrust | Buy |
| 2020-04-21 | Iniziato | Goldman | Buy |
| 2020-01-27 | Iniziato | Jefferies | Buy |
| 2020-01-10 | Iniziato | SVB Leerink | Outperform |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
Mostra tutto
Relmada Therapeutics Inc Borsa (RLMD) Ultime notizie
Why Relmada Therapeutics Inc. stock remains on watchlistsInsider Buying & Real-Time Stock Entry Alerts - mfd.ru
A | How buybacks impact Relmada Therapeutics, Inc. stock value2025 AllTime Highs & Weekly Setup with High ROI Potential - mfd.ru
Recap Report: How Relmada Therapeutics Inc. (4E2) stock reacts to new regulations - mfd.ru
Relmada Therapeutics (NASDAQ:RLMD) Trading Up 6.9%Here's Why - MarketBeat
VIX Spike: Is Relmada Therapeutics Inc a strong candidate for buy and holdJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Relmada Therapeutics Announces Pricing of Upsized Public Offerin - GuruFocus
Aug Sentiment: How do insiders feel about Relmada Therapeutics IncStop Loss & Advanced Technical Signal Analysis - baoquankhu1.vn
What MACD trends signal for Relmada Therapeutics Inc. (4E2) stockJuly 2025 Institutional & Community Verified Watchlist Alerts - mfd.ru
Can Relmada Therapeutics Inc. be the next market leader2025 Volatility Report & Fast Moving Trade Plans - mfd.ru
Does Relmada Therapeutics Inc. meet Warren Buffett’s criteria2025 Fundamental Recap & Target Return Focused Picks - mfd.ru
Relmada regains Nasdaq compliance on minimum bid price - MSN
Relmada Therapeutics Secures Critical FDA Alignment for Key Cancer Drug () - aktiencheck.de
Aug Opening: Should I invest in Relmada Therapeutics Inc. before earningsPrice Action & Low Risk Growth Stock Ideas - baoquankhu1.vn
Returns Recap: Can Relmada Therapeutics Inc deliver consistent dividendsQuarterly Portfolio Summary & Safe Entry Point Alerts - baoquankhu1.vn
Momentum Shift: How is The New York Times Company managing supply chain issues2025 Volume Leaders & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Analysts Set Relmada Therapeutics, Inc. (NASDAQ:RLMD) PT at $9.00 - Defense World
Stock Recap: Can Culp Inc maintain sales growthDay Trade & Growth Focused Investment Plans - baoquankhu1.vn
Decliners Report: Does Relmada Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Is Office Properties Income Trust in a long term uptrendWeekly Trade Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Aug Action: Is Orthofix Medical Inc stock a top performer YTD2025 Sector Review & Expert-Curated Trade Recommendations - baoquankhu1.vn
Big Money Moves: Why is Viper Energy Inc stock going downDip Buying & High Conviction Trade Alerts - baoquankhu1.vn
Is Relmada Therapeutics Inc. stock a hidden gemJuly 2025 Review & Low Risk Entry Point Tips - mfd.ru
Update Recap: Does Bioventus Inc have a competitive edgeWeekly Risk Report & Real-Time Volume Trigger Notifications - baoquankhu1.vn
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Given Average Rating of "Hold" by Analysts - MarketBeat
Zacks Research Upgrades Relmada Therapeutics (NASDAQ:RLMD) to "Hold" - MarketBeat
What’s next for Relmada Therapeutics Inc. stockJuly 2025 Levels & Weekly Breakout Opportunity Watchlist - mfd.ru
Resistance Check: What are the analyst revisions for Civitas Resources IncIs STRW stock a good investment in YEAREarnings Overview Summary & Daily Stock Trend Reports - baoquankhu1.vn
How do insiders feel about Relmada Therapeutics Inc.Quarterly Growth Report & Fast Entry High Yield Stock Tips - mfd.ru
Leerink Partners Initiates Relmada Therapeutics(RLMD.US) With Buy Rating, Announces Target Price $8 - 富途牛牛
Leerink Partners Upgrades Relmada Therapeutics (RLMD) - Nasdaq
Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential By Investing.com - Investing.com Nigeria
Leerink Partners upgrades Relmada stock to Outperform on bladder cancer treatment potential - Investing.com Nigeria
Relmada Therapeutics (NASDAQ:RLMD) Upgraded by Leerink Partners to Outperform Rating - MarketBeat
Relmada Therapeutics (RLMD) Upgraded by Leerink Partners to 'Out - GuruFocus
Targets Report: Is now the right time to enter Relmada Therapeutics IncMarket Risk Analysis & Reliable Price Breakout Alerts - baoquankhu1.vn
Tech Rally: Does Relmada Therapeutics Inc meet Warren Buffetts criteria2025 Technical Patterns & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
Bull Run: Is Relmada Therapeutics Inc in accumulation or distribution phase2025 Growth vs Value & Detailed Earnings Play Strategies - baoquankhu1.vn
Relmada’s New Phase 3 Bladder Cancer Trial Adds a Fresh Catalyst to Its Pipeline - TipRanks
FDA endorses Relmada’s registrational strategy for bladder cancer therapy - Indian Pharma Post
Is Relmada Therapeutics Inc stock affected by interest rate hikesWeekly Trend Summary & High Win Rate Trade Tips - Bộ Nội Vụ
Relmada’s BOOST phase 3 bladder cancer trial sets up a new catalyst for RLMD investors - MSN
Relmada receives FDA feedback for bladder cancer therapy trials By Investing.com - Investing.com Canada
Will Relmada Therapeutics Inc. (4E2) stock outperform energy sector in 2025Footwear buying guidance for all day wear during busy schedules focuses on foot fatigue reduction, making it helpful for judging overall value. - ulpravda.ru
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications - Investing News Network
Relmada Therapeutics (RLMD) Advances NDV-01 with FDA Guidance - GuruFocus
Relmada gets FDA alignment on NDV-01 bladder cancer trial designs - StreetInsider
Relmada Therapeutics Provides Regulatory Update Confirming - GlobeNewswire
Will Relmada Therapeutics Inc. stock benefit from infrastructure spendingForecast Cut & Low Risk High Reward Ideas - Улправда
How supply chain issues affect Relmada Therapeutics Inc. stockBuy Signal & Weekly Momentum Stock Picks - ulpravda.ru
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD) - Defense World
Relmada Therapeutics Inc Azioni (RLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
0.89%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):